1. Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy 
Kevin D. Mullen, Arun J. Sanyal, Nathan M. Bass, Fred F. Poordad, Muhammad Y. Sheikh, R. Todd Frederick, Enoch Bortey, William P. Forbes 
Clinical Gastroenterology and Hepatology 
Volume 12, Issue 8, Pages e2 (August 2014)
DOI: /j.cgh
Copyright © 2014 AGA Institute Terms and Conditions

2. Figure 1
Rates of HE-related and all-cause hospitalizations for the all-rifaximin and new-rifaximin populations in the OLM compared with patients receiving historical placebo or rifaximin in the 6-month RCT. *P < vs placebo. Inferential statistics were not conducted for the all-rifaximin and new-rifaximin populations.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2014 AGA Institute Terms and Conditions

3. Supplementary Figure 1
CONSORT flow diagram. aThe integrated safety population (all-rifaximin population, N = 392) included the new-rifaximin population plus all patients who received rifaximin during the RCT regardless of enrollment into the OLM (gray shaded boxes). CONSORT, Consolidated Standards of Reporting Trials.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2014 AGA Institute Terms and Conditions

4. Supplementary Figure 2
Antibiotic use time in the all-rifaximin population.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2014 AGA Institute Terms and Conditions